RxDoctor Payments Data

Douglas Melman, MD

Dermatology · Woodbury, NYNPI 1861464679

Payments from drug & device makers

$7,195in general payments, 2019–2025

Across 312 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arcutis Biotherapeutics, Inc.$1K
  • Johnson & Johnson$902
  • Sun Pharmaceutical Industries Inc.$512
  • Almirall LLC$510
  • AbbVie$407
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$332
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$6,83595%
  • Education$3605%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,195 in reported general payments places this provider in the 65th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$467,053
Medicare patients
1,394
Services billed
7,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErivedgeVismodegib11$142,271
Dupixent SyringeDupilumab18$64,469
Dupixent PenDupilumab12$60,010
KlisyriTirbanibulin18$19,588
JubliaEfinaconazole13$12,246
Clobetasol Propionate162$6,946
Ketoconazole319$6,030
Mupirocin514$3,998
Metronidazole64$3,463
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc60$2,893
Triamcinolone Acetonide208$2,383
Fluocinonide47$2,023
Gentamicin Sulfate46$2,023
Clindamycin Phosphate55$1,860
CiclopiroxCiclopirox Olamine82$1,679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Erivedge$168$142,27111 claims
Almirall LLCKlisyri$510$19,58818 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$332$12,24613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,151 dermatology providers in New York.

Other dermatology in Woodbury

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →